Last $2.35 USD
Change Today -0.04 / -1.67%
Volume 36.9K
CDXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Open
$2.43
Previous Close
$2.39
Day High
$2.43
Day Low
$2.31
52 Week High
10/13/14 - $3.30
52 Week Low
12/24/13 - $1.24
Market Cap
92.9M
Average Volume 10 Days
84.6K
EPS TTM
$-0.72
Shares Outstanding
39.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

125 Employees
Last Reported Date: 03/13/14
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $334.8K
Special Advisor
Total Annual Compensation: $68.8K
Compensation as of Fiscal Year 2013.

codexis inc (CDXS) Key Developments

Codexis, Inc. Approves the Resignation of Pedro Mizutan as Board Member

At the meeting of the board of directors of Codexis, Inc. held on November 6, 2014, Pedro Mizutani resigned from the board effective November 6, 2014.

Codexis, Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Codexis, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues were $7,472,000 against $3,943,000 a year ago, driven in part by the higher R&D service revenue it has achieved in any quarter in the last 2 years. Loss from operations was $4,255,000 against $9,214,000 a year ago. Loss before provision for income taxes was $4,309,000 against $9,227,000 a year ago. Net loss was $4,562,000 or $0.12 basic and diluted per share against $9,262,000 or $0.24 basic and diluted per share a year ago. Non-GAAP net loss was $1,932,000 or $0.05 basic and diluted per share against $6,026,000 or $0.16 basic and diluted per share a year ago. For the nine-month period, the company reported total revenues were $21,116,000 against $22,397,000 a year ago. Loss from operations was $19,562,000 against $31,295,000 a year ago. Loss before provision for income taxes was $19,730,000 against $31,530,000 a year ago. Net loss was $19,416,000 or $0.51 basic and diluted per share against $31,489,000 or $0.83 basic and diluted per share a year ago. Non-GAAP net loss was $8,609,000 or $0.23 basic and diluted per share against $20,290,000 or $0.53 basic and diluted per share a year ago. Codexis is maintaining its previously stated 2014 financial guidance, which includes revenues of between $35 million and $38 million, representing growth of 10% to 19% compared to the prior year. Gross margins are expected in the range of 70% to 75% as a % of total revenues, which would reflect a significant increase from the 54% gross margin delivered in 2013. Codexis continues to expect to achieve positive cash flow from operations for fiscal year 2014.

Codexis, Inc. Appoints Pam Cheng to its Board of Directors

Codexis, Inc. announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $2.35 USD -0.04

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $23.27 USD +0.18
Koninklijke DSM NV €52.00 EUR 0.00
Novozymes A/S kr274.40 DKK -3.20
Takasago International Corp ¥577.00 JPY +32.00
View Industry Companies
 

Industry Analysis

CDXS

Industry Average

Valuation CDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit www.codexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.